On Jul. 9, 2020, Royal Philips announced it had formed a strategic collaboration with BioIntelliSense, a continuous health monitoring and clinical intelligence company, to integrate its BioStickerﾙ medical device into Philipsﾒ remote patient monitoring (RPM) offering to help monitor at-risk patients from the hospital into the home.

Philipsﾒ solutions can enhance how clinicians monitor patient populations living with chronic conditions ﾖ including diabetes, cancer, congestive heart failure and more – in their homes with passive monitoring of key vital signs, physiological biometrics and symptomatic events via a discreet wearable patch for monitoring up to 30 days.